Suppr超能文献

一种用于活细胞中激酶的基于探针的靶点结合分析方法。

A Probe-Based Target Engagement Assay for Kinases in Live Cells.

作者信息

Glocker Ursula M, Braun Florian, Eberl H Christian, Bantscheff Marcus

机构信息

Cellzome, A GSK Company, Heidelberg, Germany.

Chemical Synthesis Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.

出版信息

Mol Cell Proteomics. 2025 Apr 3;24(5):100963. doi: 10.1016/j.mcpro.2025.100963.

Abstract

The efficacy and safety of kinase inhibitor drugs are largely influenced by their selectivity. Available profiling technologies are primarily based on overexpressed or endogenously expressed kinases in cell extracts. We compared kinase capture with the cell penetrant covalent probe XO44 to three derivatives and found that replacing the alkyne handle with a trans-cyclooctene group allowed the development of a more robust kinase capture and enrichment protocol. An intracellular chemoproteomics target profiling and engagement assay was devised by optimizing probe concentration and incubation time and using an isobaric mass tag-based strategy for relative quantification. Comparing intracellular kinase profiles of the marketed drug dasatinib and the tool compound dinaciclib with the lysate-based kinobeads assay revealed excellent agreement in rank-order of binding. Dinaciclib showed a systematic shift to higher ICs, suggesting that intracellular cosubstrate concentrations, cell penetration of the compound, as well as kinase localization and complexes in live cells influence target profiles. Further, we show that sepiapterin reductase SPR and multidrug resistance protein 1 ABCC1 are off-targets of kinase inhibitor scaffolds with potential implications on efficacy and safety.

摘要

激酶抑制剂药物的疗效和安全性在很大程度上受其选择性影响。现有的分析技术主要基于细胞提取物中过表达或内源性表达的激酶。我们将激酶捕获与细胞穿透性共价探针XO44及其三种衍生物进行了比较,发现用反式环辛烯基团取代炔烃手柄能够开发出一种更强大的激酶捕获和富集方案。通过优化探针浓度和孵育时间,并使用基于等压质量标签的策略进行相对定量,设计了一种细胞内化学蛋白质组学靶点分析和结合测定方法。将市售药物达沙替尼和工具化合物地西他滨的细胞内激酶谱与基于裂解物的激酶磁珠分析进行比较,结果显示结合顺序具有极佳的一致性。地西他滨显示出向更高IC值的系统性偏移,这表明细胞内共底物浓度、化合物的细胞穿透性以及活细胞中的激酶定位和复合物会影响靶点谱。此外,我们表明蝶呤还原酶SPR和多药耐药蛋白1 ABCC1是激酶抑制剂支架的脱靶,对疗效和安全性可能有影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/365c/12076712/f29678c9cbac/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验